Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N.
Issa GC, et al. Among authors: bhalla k.
Blood Adv. 2023 Mar 28;7(6):933-942. doi: 10.1182/bloodadvances.2022008316.
Blood Adv. 2023.
PMID: 36322818
Free PMC article.